FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3196383959> ?p ?o ?g. }

• W3196383959 endingPage "413" @default.
• W3196383959 startingPage "392" @default.
• W3196383959 abstract "Amorphous solid dispersions (ASDs) are of great interest due to their ability to enhance the delivery of poorly soluble drugs. Recent studies have shown that, in addition to acting as a crystallization inhibitor, the polymer in an ASD plays a role in controlling the rate of drug release, notably in congruently releasing formulations, where both the drug and polymer have similar normalized release rates. The aim of this study was to compare the solid-state stability and release performance of ASDs when formulated with neutral and enteric polymers. One neutral (polyvinylpyrrolidone-vinyl acetate copolymer, PVPVA) and four enteric polymers (hypromellose acetate succinate; hypromellose phthalate; cellulose acetate phthalate, CAP; methacrylic acid-methyl methacrylate copolymer, Eudragit L 100) were used to formulate binary ASDs with lumefantrine, a hydrophobic and weakly basic antimalarial drug. The normalized drug and polymer release rates of lumefantrine-PVPVA ASDs up to 35% drug loading (DL) were similar and rapid. No drug release from PVPVA systems was detected when the DL was increased to 40%. In contrast, ASDs formulated with enteric polymers showed a DL-dependent decrease in the release rates of both the drug and polymer, whereby release was slower than for PVPVA ASDs for DLs < 40% DL. Drug release from CAP and Eudragit L 100 systems was the slowest and drug amorphous solubility was not achieved even at 5% DL. Although lumefantrine-PVPVA ASDs showed fast release, they also showed rapid drug crystallization under accelerated stability conditions, while the ASDs with enteric polymers showed much greater resistance to crystallization. This study highlights the importance of polymer selection in the formulation of ASDs, where a balance between physical stability and dissolution release must be achieved." @default.
• W3196383959 created "2021-09-13" @default.
• W3196383959 creator A5015225945 @default.
• W3196383959 creator A5020380530 @default.
• W3196383959 creator A5090835640 @default.
• W3196383959 date "2021-09-08" @default.
• W3196383959 modified "2023-10-11" @default.
• W3196383959 title "Balancing Solid-State Stability and Dissolution Performance of Lumefantrine Amorphous Solid Dispersions: The Role of Polymer Choice and Drug–Polymer Interactions" @default.
• W3196383959 cites W1697297771 @default.
• W3196383959 cites W1697337825 @default.
• W3196383959 cites W1795494388 @default.
• W3196383959 cites W1966385056 @default.
• W3196383959 cites W1968834637 @default.
• W3196383959 cites W1970082198 @default.
• W3196383959 cites W1973001985 @default.
• W3196383959 cites W1989461604 @default.
• W3196383959 cites W2001533174 @default.
• W3196383959 cites W2032268755 @default.
• W3196383959 cites W2039639971 @default.
• W3196383959 cites W2054641528 @default.
• W3196383959 cites W2075003681 @default.
• W3196383959 cites W2077594374 @default.
• W3196383959 cites W2088981438 @default.
• W3196383959 cites W2090726723 @default.
• W3196383959 cites W2091551182 @default.
• W3196383959 cites W2094039623 @default.
• W3196383959 cites W2103059913 @default.
• W3196383959 cites W2105324121 @default.
• W3196383959 cites W2117932143 @default.
• W3196383959 cites W2118623650 @default.
• W3196383959 cites W2123167484 @default.
• W3196383959 cites W2126269750 @default.
• W3196383959 cites W2131419097 @default.
• W3196383959 cites W2139935246 @default.
• W3196383959 cites W2209586872 @default.
• W3196383959 cites W2267776945 @default.
• W3196383959 cites W2317383153 @default.
• W3196383959 cites W2320607110 @default.
• W3196383959 cites W2320765608 @default.
• W3196383959 cites W2330809708 @default.
• W3196383959 cites W2346169493 @default.
• W3196383959 cites W2410270548 @default.
• W3196383959 cites W2471266503 @default.
• W3196383959 cites W2545238138 @default.
• W3196383959 cites W2558536136 @default.
• W3196383959 cites W2622240386 @default.
• W3196383959 cites W2641848379 @default.
• W3196383959 cites W2759450909 @default.
• W3196383959 cites W2768018462 @default.
• W3196383959 cites W2790356442 @default.
• W3196383959 cites W2895560947 @default.
• W3196383959 cites W2911318662 @default.
• W3196383959 cites W2911693126 @default.
• W3196383959 cites W2913392672 @default.
• W3196383959 cites W2989431021 @default.
• W3196383959 cites W3002996103 @default.
• W3196383959 cites W3007149040 @default.
• W3196383959 cites W3009735482 @default.
• W3196383959 cites W3011259025 @default.
• W3196383959 cites W3043380660 @default.
• W3196383959 cites W3043539061 @default.
• W3196383959 cites W3049409940 @default.
• W3196383959 cites W3149581335 @default.
• W3196383959 doi "https://doi.org/10.1021/acs.molpharmaceut.1c00481" @default.
• W3196383959 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34494842" @default.
• W3196383959 hasPublicationYear "2021" @default.
• W3196383959 type Work @default.
• W3196383959 sameAs 3196383959 @default.
• W3196383959 citedByCount "33" @default.
• W3196383959 countsByYear W31963839592021 @default.
• W3196383959 countsByYear W31963839592022 @default.
• W3196383959 countsByYear W31963839592023 @default.
• W3196383959 crossrefType "journal-article" @default.
• W3196383959 hasAuthorship W3196383959A5015225945 @default.
• W3196383959 hasAuthorship W3196383959A5020380530 @default.
• W3196383959 hasAuthorship W3196383959A5090835640 @default.
• W3196383959 hasBestOaLocation W31963839591 @default.
• W3196383959 hasConcept C127413603 @default.
• W3196383959 hasConcept C155574463 @default.
• W3196383959 hasConcept C178790620 @default.
• W3196383959 hasConcept C185592680 @default.
• W3196383959 hasConcept C192562407 @default.
• W3196383959 hasConcept C203036418 @default.
• W3196383959 hasConcept C2777570183 @default.
• W3196383959 hasConcept C2778551929 @default.
• W3196383959 hasConcept C2780077769 @default.
• W3196383959 hasConcept C42360764 @default.
• W3196383959 hasConcept C43617362 @default.
• W3196383959 hasConcept C521977710 @default.
• W3196383959 hasConcept C56052488 @default.
• W3196383959 hasConcept C77281830 @default.
• W3196383959 hasConcept C88380143 @default.
• W3196383959 hasConceptScore W3196383959C127413603 @default.
• W3196383959 hasConceptScore W3196383959C155574463 @default.
• W3196383959 hasConceptScore W3196383959C178790620 @default.
• W3196383959 hasConceptScore W3196383959C185592680 @default.
• W3196383959 hasConceptScore W3196383959C192562407 @default.
• W3196383959 hasConceptScore W3196383959C203036418 @default.

• next